IGM Biosciences has reported strategic and clinical updates for engineered IgM antibody programs, with a recent focus on autoimmune and inflammatory diseases. Company developments have included pipeline pivots, discontinuation of imvotamab and IGM-2644, restructuring actions, workforce reductions, governance changes, quarterly operating results, capital resources, and investor conference presentations.
Updates have also addressed bispecific T cell engager candidates, including imvotamab as a CD20 x CD3 program and IGM-2644 as a CD38 x CD3 program, as well as clinical disclosures in autoimmune indications such as rheumatoid arthritis and systemic lupus erythematosus.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.